糖尿病药物的研究进展
|
摘要
糖尿病是一组以高血糖为特征的代谢性疾病,近些年来它的发生率越来越高。该文主要阐释糖尿病的发病机制及治疗糖尿病药物的研究进展。综合近几年国内外相关的文献,该文总结了糖尿病发病机理及降糖药物的研究进展。糖尿病是由遗传因素、免疫功能紊乱、微生物感染及其毒素、自由基毒素、精神因素等等各种致病因子作用于机体导致胰岛功能减退、胰岛素抵抗等引起。基于糖尿病的不同发病机制,治疗糖尿病的药物也多种多样。对糖尿病的发病机制及不同作用机制的降糖药物进行阐述,这将对糖尿病的治疗具有重大意义。
The diabetes is a metabolic disease with hyperglycemia, recently, the incidence rate of the diabetes is higher and higher, and the paper mainly elaborates the onset mechanism of diabetes and research progress of treatment diabetes drugs according to the related literatures at home and abroad, and the diabetes is caused by the insulin hypofunction and insulin resistance due to various virulence factors such as genetic factors, immune dysfunction, microbial infection and its toxins, free radical toxins, and mental factors. The treatment drugs of diabetes are multiple based on different pathogenesis,and the elaboration of diabetes pathogenesis and different functional mechanism of hypoglycemic drugs is of great significance to the treatment of diabetes.
The diabetes is a metabolic disease with hyperglycemia, recently, the incidence rate of the diabetes is higher and higher, and the paper mainly elaborates the onset mechanism of diabetes and research progress of treatment diabetes drugs according to the related literatures at home and abroad, and the diabetes is caused by the insulin hypofunction and insulin resistance due to various virulence factors such as genetic factors, immune dysfunction, microbial infection and its toxins, free radical toxins, and mental factors. The treatment drugs of diabetes are multiple based on different pathogenesis,and the elaboration of diabetes pathogenesis and different functional mechanism of hypoglycemic drugs is of great significance to the treatment of diabetes.
引文
[1]Alam U,Asghar O,Azmi S,et al.General aspects of diabetes mellitus[J].Handbook of clinical neurology,2014,126:211-222.
[2]Michels A,Zhang L,Khadra A,Kushner JA,Redondo MJ,Pietropaolo M:Prediction and prevention of type 1 diabetes:update on success of prediction and struggles at prevention[J].Pediatric diabetes,2015,16(7):465-484.
[3]Zhu X,Wu C,Qiu S,et al.Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2diabetes:systematic review and meta-analysis[J].Nutrition&metabolism,2017,14:60.
[4]De Fronzo RA,Eldor R,Abdul-Ghani M.Pathophysiologic approach to therapy in patients with newly diagnosed type 2diabetes[J].Diabetes care,2013,36 Suppl 2:S127-138.
[5]Schwartz SS,Epstein S,Corkey BE,et al.The Time Is Right for a New Classification System for Diabetes:Rationale and Implications of the beta-Cell-Centric Classification Schema[J].Diabetes care,2016,39(2):179-186.
[6]Thrasher J.Pharmacologic Management of Type 2 Diabetes Mellitus:Available Therapies[J].The American journal of cardiology,2017,120(1S):S4-S16.
[7]Kawamori R,Kaku K,Hanafusa T,et al.Clinical study of repaglinide efficacy and safety in type 2 diabetes mellitus patients with blood glucose levels inadequately controlled by sitagliptin[J].Journal of diabetes investigation,2016,7(2):253-259.
[8]Kesavadev J,Pillai PBS,Shankar A,et al.Sitagliptin 100 mg vs glimepiride 1-3 mg as an add-on to insulin and metformin in type 2 diabetes[J].Endocrine connections,2017.
[9]Seino S.Cell signalling in insulin secretion:the molecular targets of ATP,c AMP and sulfonylurea[J].Diabetologia,2012,55(8):2096-2108.
[10]Scott LJ.Repaglinide:a review of its use in type 2 diabetes mellitus[J].Drugs,2012,72(2):249-272.
[11]Garber AJ,Abrahamson MJ,Barzilay JI,et al.Consensus Statement by the American Association of Clinical Endocri nologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm-2017 Executive Summary[J].Endocrine practice:official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists,2017,23(2):207-238.
[12]American Diabetes A.Pharmacologic Approaches to Glycemic Treatment[J].Diabetes care,2017,40(Suppl 1):S64-S74.
[13]Inzucchi SE,Tunceli K,Qiu Y,et al.Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy[J].Diabetes,obesity&metabolism,2015,17(10):956-964.
[14]Monsalve FA,Pyarasani RD,Delgado-Lopez F,et al.Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases[J].Mediators of inflamma tion,2013,2013:549627.
[15]Fuchtenbusch M,Standl E,Schatz H.Clinical efficacy of new thiazolidinediones and glinides in the treatment of type2 diabetes mellitus[J].Experimental and clinical endocrin ology&diabetes:official journal,German Society of Endocrinology and German Diabetes Association,2000,108(3):151-163.
[16]Li S,Xiao J,Ji L,et al.BMI and waist circumference are associated with impaired glucose metabolism and type 2diabetes in normal weight Chinese adults[J].Journal of diabetes and its complications,2014,28(4):470-476.
[17]Lin SD,Wang JS,Hsu SR,et al.The beneficial effect of alpha-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin:preliminary data[J].Journal of diabetes and its complications,2011,25(5):332-338.
[18]Ma RC.Acarbose:an alternative to metformin for first-line treatment in type 2 diabetes[J].The lancet Diabetes&endocrinology,2014,2(1):6-7.
[19]Madsbad S.Review of head-to-head comparisons of gluca gon-like peptide-1 receptor agonists[J].Diabetes,obesity&metabolism,2016,18(4):317-332.
[20]Thornberry NA,Gallwitz B.Mechanism of action of inhibi tors of dipeptidyl-peptidase-4(DPP-4)[J].Best practice&research Clinical endocrinology&metabolism,2009,23(4):479-486.
[2]Michels A,Zhang L,Khadra A,Kushner JA,Redondo MJ,Pietropaolo M:Prediction and prevention of type 1 diabetes:update on success of prediction and struggles at prevention[J].Pediatric diabetes,2015,16(7):465-484.
[3]Zhu X,Wu C,Qiu S,et al.Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2diabetes:systematic review and meta-analysis[J].Nutrition&metabolism,2017,14:60.
[4]De Fronzo RA,Eldor R,Abdul-Ghani M.Pathophysiologic approach to therapy in patients with newly diagnosed type 2diabetes[J].Diabetes care,2013,36 Suppl 2:S127-138.
[5]Schwartz SS,Epstein S,Corkey BE,et al.The Time Is Right for a New Classification System for Diabetes:Rationale and Implications of the beta-Cell-Centric Classification Schema[J].Diabetes care,2016,39(2):179-186.
[6]Thrasher J.Pharmacologic Management of Type 2 Diabetes Mellitus:Available Therapies[J].The American journal of cardiology,2017,120(1S):S4-S16.
[7]Kawamori R,Kaku K,Hanafusa T,et al.Clinical study of repaglinide efficacy and safety in type 2 diabetes mellitus patients with blood glucose levels inadequately controlled by sitagliptin[J].Journal of diabetes investigation,2016,7(2):253-259.
[8]Kesavadev J,Pillai PBS,Shankar A,et al.Sitagliptin 100 mg vs glimepiride 1-3 mg as an add-on to insulin and metformin in type 2 diabetes[J].Endocrine connections,2017.
[9]Seino S.Cell signalling in insulin secretion:the molecular targets of ATP,c AMP and sulfonylurea[J].Diabetologia,2012,55(8):2096-2108.
[10]Scott LJ.Repaglinide:a review of its use in type 2 diabetes mellitus[J].Drugs,2012,72(2):249-272.
[11]Garber AJ,Abrahamson MJ,Barzilay JI,et al.Consensus Statement by the American Association of Clinical Endocri nologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm-2017 Executive Summary[J].Endocrine practice:official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists,2017,23(2):207-238.
[12]American Diabetes A.Pharmacologic Approaches to Glycemic Treatment[J].Diabetes care,2017,40(Suppl 1):S64-S74.
[13]Inzucchi SE,Tunceli K,Qiu Y,et al.Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy[J].Diabetes,obesity&metabolism,2015,17(10):956-964.
[14]Monsalve FA,Pyarasani RD,Delgado-Lopez F,et al.Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases[J].Mediators of inflamma tion,2013,2013:549627.
[15]Fuchtenbusch M,Standl E,Schatz H.Clinical efficacy of new thiazolidinediones and glinides in the treatment of type2 diabetes mellitus[J].Experimental and clinical endocrin ology&diabetes:official journal,German Society of Endocrinology and German Diabetes Association,2000,108(3):151-163.
[16]Li S,Xiao J,Ji L,et al.BMI and waist circumference are associated with impaired glucose metabolism and type 2diabetes in normal weight Chinese adults[J].Journal of diabetes and its complications,2014,28(4):470-476.
[17]Lin SD,Wang JS,Hsu SR,et al.The beneficial effect of alpha-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin:preliminary data[J].Journal of diabetes and its complications,2011,25(5):332-338.
[18]Ma RC.Acarbose:an alternative to metformin for first-line treatment in type 2 diabetes[J].The lancet Diabetes&endocrinology,2014,2(1):6-7.
[19]Madsbad S.Review of head-to-head comparisons of gluca gon-like peptide-1 receptor agonists[J].Diabetes,obesity&metabolism,2016,18(4):317-332.
[20]Thornberry NA,Gallwitz B.Mechanism of action of inhibi tors of dipeptidyl-peptidase-4(DPP-4)[J].Best practice&research Clinical endocrinology&metabolism,2009,23(4):479-486.